IMUNON

Developing medicines harnessing the capability of DNA to power the body's immune system.

HEADQUARTERS
Lawrenceville, NJ

EXCHANGE
Nasdaq

TICKER
IMNN

STAGE
Clinical Stage Biotechnology

FOCUS
Ovarian Cancer Immunotherapy

LEAD PROGRAM
IMNN-001 (OVATION 3 Phase 3)

FDA STATUS
Fast Track & Orphan Drug Designation

INVESTOR RELATIONS
imunon@KCSA.com

www.imunon.com

Capital Structure

SHARES OUTSTANDING
~4.2M

PUBLIC FLOAT
~4.0M est.

MARKET CAP
~$8.2M

SHARE PRICE
$2.10

52-WEEK HIGH / LOW
$10.43 – $1.70

TOTAL DEBT (at 3/31/26)
None

CASH & EQUIVALENTS (at 3/31/26)
$4.8M

About Imunon

Imunon, Inc. (Nasdaq: IMNN) is a clinical-stage biopharmaceutical company developing first-in-class DNA-based immunotherapies. Its lead program, IMNN-001, delivers the immune-activating cytokine IL-12 locally to the ovarian tumor microenvironment — avoiding the systemic toxicity that limited earlier IL-12 therapies.

Ovarian Cancer: Significant Unmet Need

300K+	40%	80%	30 Yrs
New Cases Worldwide / Year	5-Year Survival Rate	Diagnosed at Advanced Stage	No Meaningful SoC Advance

Lead Program: IMNN-001

IMNN-001 is an IL-12 DNA plasmid delivered intraperitoneally via Imunon's proprietary TheraPlas® nanoparticle platform. Unlike prior IL-12 therapies that caused severe systemic toxicity, IMNN-001 produces durable, localized IL-12 expression directly in the tumor microenvironment — safely and efficiently converting immunosuppressed "cold" tumors into immunologically active environments without systemic side effects.

Phase 2 Results: OVATION 2 (112 Patients)

+14.7 mos.	+24.2 mos.	0
Median OS Benefit vs. SoC Alone (45.1 vs. 30.4 mos)	Median OS Benefit w/ PARP Inhibitors (65.6 vs. 41.4 mos)	Serious Immune-Related Adverse Events Observed

Phase 3: OVATION 3 — Actively Enrolling

- 500-patient, randomized 1:1, Phase 3 trial — primary endpoint: Overall Survival
- Enrollment ahead of plan; 50% enrollment targeted Q1 2028, full enrollment Q1 2029
- Two planned interim analyses for potential early stopping and BLA submission
- FDA aligned on protocol & CMC; independent DMC recommended trial continuation (June 2026)

Investment Highlights

- First-in-class IL-12 immunotherapy with a differentiating safety profile
- Phase 2 data demonstrate >14-month OS benefit — no other frontline drug with comparable benefit
- FDA Fast Track and Orphan Drug designation in the US and EU
- Proprietary TheraPlas® platform applicable across multiple oncology indications
- Peak US/Canada revenue potential estimated at $3 billion
- Management estimates 85%+ gross margin at commercial scale, supported by low-cost in-house manufacturing
- $100M total 5-year program cost with a structured tranche financing approach

Recent Developments

- Independent DMC recommended OVATION 3 continuation after planned safety review (June 2026)
- FDA aligned on Phase 3 protocol; confirmed path to BLA filing (May 2026)
- OVATION 2 data published in Gynecologic Oncology; presented at ASCO 2025
- Completed 1-for-15 reverse split (July 2025); pursuing financing to fully fund Phase 3

Product Pipeline

Platform	Delivery	Program	Indication(s)	Discovery	IND	Phase 1	Phase 2	Phase 3
TheraPlas	IP	IL-12 (OVATION 3)	Newly Diagnosed Adv. Ovarian Cancer	IMNN-001				enrolling
		IL-12 + Avastin*	Newly Diagnosed Adv. Ovarian Cancer	IMNN-001			enrolling	
		IL-12 (OVATION 2)	Newly Diagnosed Adv. Ovarian Cancer	IMNN-001			complete	
		IL-12 + Checkpoint Inhib.	Newly Diagnosed Adv. Ovarian Cancer	IMNN-001		Ready		
		IL-12	Colorectal Cancer	IMNN-001		Ready		
		IL-12	Pancreatic Cancer	IMNN-001		Ready		
	Intra-tumoral	IL-12	Glioblastoma	IMNN-001				

This factsheet contains forward-looking statements. All clinical data from IMUNON's SEC filings and published research. See company filings for full risk factors. Market data as of June 2026; company financials as of March 31, 2026.